Market capitalization | $1.07b |
Enterprise Value | $800.08m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.88 |
P/S ratio (TTM) P/S ratio | 6.49 |
P/B ratio (TTM) P/B ratio | 1.40 |
Revenue growth (TTM) Revenue growth | 13,698.99% |
Revenue (TTM) Revenue | $164.07m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
13 Analysts have issued a Iovance Biotherapeutics Inc forecast:
13 Analysts have issued a Iovance Biotherapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 164 164 |
13,687%
13,687%
|
|
Gross Profit | 18 18 |
148%
148%
|
|
EBITDA | -352 -352 |
18%
18%
|
EBIT (Operating Income) EBIT | -395 -395 |
14%
14%
|
Net Profit | -372 -372 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Head office | United States |
CEO | Frederick Vogt |
Employees | 838 |
Founded | 2007 |
Website | www.iovance.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.